|
Link to this page
Your search term(s) "Erectile Dysfunction" returned 25 results.
Displaying all search results.
Male Sexual Dysfunction. IN: Tanagho, E.; McAninch, J., eds. Smith’s General Urology. 17th ed. Columbus, OH: McGraw Hill. 2008. pp 589-610.
This chapter about male sexual dysfunction is from an updated edition of a comprehensive textbook about urology that offers an overview of the diagnosis and treatment of diseases and disorders common to the genitourinary tract. The authors note that advances in pharmacologic therapy for erectile dysfunction (ED), coupled with a better understanding of male sexual dysfunction achieved through research on the mechanism, neurophysiology, and pharmacology of penile erection, have resulted in greater numbers of patients seeking primary and specialty care for sexual concerns. Erectile function can now be evaluated by response to oral drug agents at home or intracavernous injection of vasoactive agents in the office, and improved diagnostic tests can differentiate among types of impotence. Topics covered include the physiology of penile erection, innervation of the penis, anatomy and hemodynamics of penile erection, the mechanism of penile erection, hormones and sexual function, neurotransmitters and pharmacology of erection, the molecular mechanism of smooth-muscle contraction and relaxation, signal transduction in penile erection, the epidemiology of male sexual dysfunction, the classification of ED, diagnosis and treatment, advanced testing for ED, the nonsurgical treatment of ED, penile vascular surgery, penile prosthesis, and male sexual dysfunction involving emission, ejaculation, and orgasm. The chapter is illustrated with black-and-white drawings and photographs. The chapter concludes with an extensive list of references, categorized by topic. 6 figures. 6 tables. 77 references.
Full Record Printer Friendly Version
Erectile Dysfunction and Peyronie's Disease. IN: Litwin, M.S.; Saigal, C.S., eds. Urologic Diseases in America. Bethesda, MD: National Kidney and Urologic Diseases Information Clearinghouse. pp. 483-530.
Male sexual health has taken on increased importance as the United States population ages, develops co-existing medical conditions, and undergoes interventions that can affect sexual health. This chapter focuses on two major areas of male sexual health, erectile dysfunction (ED) and Peyronie’s disease (PD). The chapter is from a lengthy text that offers a comprehensive portrait of the illness burden and resource use associated with the major urologic diseases in the United States. For each condition, the authors discuss definition and diagnosis; prevalence and incidence; risk factors; clinical evaluation; trends in health care resource utilization for this condition, specifically inpatient and outpatient care; emergency room care and surgical trends; and economic impact. The section on ED also considers the pharmacologic management of ED. A final section offers recommendations on the topic of diagnosis, treatment, and areas of needed research. The authors conclude that the treatments used for ED, as measured by hospital outpatient, ambulatory surgery, physician office visits, and cost reimbursement data, suggest shifting forms of health care utilization. Available data on PD is limited and it is difficult to assess accurately the true prevalence and impact of PD. 3 figures. 36 tables. 36 references.
Full Record Printer Friendly Version
Erection Problems: What Men Need to Know. Los Problemas de Ereccion: Lo Que Los Hombres Deben Saber. Bethesda, MD: National Kidney and Urologic Diseases Information Clearinghouse. 2007. 4 p.
This fact sheet provides information about erectile dysfunction. Written in a question-and-answer format, the fact sheet discusses the normal physiology of an erection, the possible causes of erectile dysfunction, and treatment options, including counseling, oral medications, injection, vacuum devices, and penile implants. The fact sheet refers readers to the National Kidney and Urologic Diseases Information Clearinghouse (NIKUDIC) for more information (www.kidney.niddk.nih.gov). Two pages of the fact sheet are in English and the same information is repeated in Spanish on the other two pages.
Full Record Printer Friendly Version
Beyond Viagra: What are Your Options?. Mayo Clinic Health Letter. 24(1): 7. January 2006.
This brief newsletter article reviews the treatment options for erectile dysfunction (ED). The article begins with an overview of the causes of ED, which can include physical causes such as diabetes, high blood pressure, or cardiovascular conditions and other causes including low levels of sexual desire (libido) or relationship issues. Surgeries to treat certain cancers (including prostate cancer) or drug side effects can also affect erectile function. Treatment can include one of three oral medications: sildenafil (Viagra), vardenafil (Levitra), or tadalafil (Cialis). The author explains how each of these drugs works and how they differ from one another. A final section outlines some of the other, non-drug treatment options for ED, including injectable drugs, vacuum devices, hormone therapy, and penile implants. Readers are encouraged to work closely with their health care provider to find an ED treatment that works for their own individual situation.
Full Record Printer Friendly Version
Drugs Used in the Treatment of Erectile Dysfunction. IN: Eardley, I., et al, eds. Drug Treatment in Urology. Williston, VT: Blackwell Publishing Inc. 2006. pp. 39-61.
This chapter on drugs used in the treatment of erectile dysfunction (ED) is from a book that offers a comprehensive summary of the role of pharmacology in urology. An introductory section reviews the physiology of erection, the causes of ED, and the principles of drug therapy to improve erectile function. The chapter then covers specific drugs, including the orally active phosphodiesterase type 5 (PDE5) inhibitors sildenafil, tadalafil, and vardenafil; centrally acting agents, notably apomorphine; and other occasionally-used oral agents, including phentolamine, yohimbine, and trazodone. The author then discusses the use of intracavernosal and intraurethral alprostadil, testosterone therapy, and agents currently under development. The author concludes that the PDE5 inhibitors remain the first line of therapy for most men with ED. Injectables are indicated following failure of initial oral therapy. 1 figure. 9 tables. 68 references.
Full Record Printer Friendly Version
Erectile Dysfunction and Peyronie’s Disease. IN: Kellogg Parsons, J.; James Wright, E., eds. Brady Urology Manual. New York, NY: Informa Healthcare USA. 2006. pp 51-62.
This chapter about erectile dysfunction (ED) and Peyronie’s disease is from a reference handbook that offers a comprehensive overview of urology, presented in outline and bulleted formats for ease of access in the busy health care world of hospital emergency rooms and outpatient clinics. The authors define ED as the consistent or recurrent inability of a man to attain and/or maintain a penile erection sufficient for sexual activity. They cover the different types of ED, epidemiology, physiology of erection, patient evaluation, and treatment options, including drug therapy, intracavernous injection therapy, intraurethral injection therapy, vacuum constriction devices, and penile prosthesis. The second section discusses Peyronie’s disease, a localized connective tissue disorder of the penis, characterized by changes in the collagen composition of the tunica albuginea. The authors discuss epidemiology, pathophysiology, presentation and evaluation, medical therapy, and surgical therapy. Peyronie’s disease typically presents as a palpable penile plaque, penile pain, penile curvature, and ED. Treatment includes medical therapy and surgery. The chapter concludes with a list of references for additional reading. 1 figure. 1 table. 49 references.
Full Record Printer Friendly Version
Erectile Dysfunction: A Patient Quick-Guide to Cause, Diagnosis, and Treatment. Augusta, GA: Augusta Medical Systems. 2006. 22 p.
This booklet provides information on the causes and diagnoses of erectile dysfunction and on all currently-accepted therapies. Erectile dysfunction (ED) is defined as the repeated inability to achieve or sustain an erection sufficient for sexual intercourse. The authors review three factors that can lead to ED: psychological factors, ranging from depression to self-esteem issues; physical factors, which can include trauma (from surgery or injury) and diseases (diabetes, cardiovascular disease); and drug effects, including those from prescription, non-prescription, and recreational or illegal substances. These factors can interrupt the delicate process of mental, nervous, and vascular systems that must work together to produce an erection. One section of the booklet explains what to expect from the first physician visit, including commonly used diagnostic tests. The authors then discuss treatments, including psychotherapy, vacuum therapy systems, oral medications (sildenafil, vardenafil, tadalafil), self-injection, urethral suppositories, and penile implants. The authors also consider the side effects and costs of each of these treatment options. A final section describes the work of the American Urological Association and refers readers to the book-length version of this booklet, published in June 2006 (ISBN: 0-9868949-1-2). 16 figures. 2 tables. 14 references.
Full Record Printer Friendly Version
Sexual Health. IN: Blueprint for Men's Health: A Guide to a Healthy Lifestyle. Washington, DC: Men's Health Network. June 2006. pp. 21-25.
This chapter on sexual health is from a booklet that reviews a wide spectrum of health issues, focusing on health promotion and prevention for men. In this chapter, the author discusses the most common sexual problems in men and how to manage them. Topics include erectile dysfunction (ED), safe sex and sexually transmitted diseases (STDs), birth control and contraception, and changes in sexuality with aging. The author reminds readers that one's overall health can have an impact on sexuality, so taking steps to improve overall health can help reduce or even eliminate problems such as ED. Readers are encouraged to talk with their health care provider about any concerns they may have in this area.
Full Record Printer Friendly Version
Subfertility and Male Sexual Dysfunction. IN: Dawson, C.; Whitfield, H.N., eds. ABC of Urology. Williston, VT: Blackwell Publishing Inc. 2006. pp. 18-21.
This chapter on subfertility and male sexual dysfunction is from an atlas of basic urologic problems that is designed to help general practitioners address the ever-increasing number of patients presenting to their offices with urological problems. Subfertility is defined as failure to conceive after regular unprotected sexual intercourse over a period of one year; this chapter only considers male subfertility. The author reviews the causes of male factor infertility and the diagnostic tests done to assess the condition. The author briefly discusses assisted reproductive techniques that can be used to treat couples affected by subfertility. The second section of the chapter covers erectile dysfunction (ED), its risk factors, symptoms, diagnosis, and treatment. Two brief final sections consider Peyronie disease and androgen decline in the aging male. The chapter features a few pages of text, summaries of information in charts and tables, a list of recommendations for further reading, and full-color photographs and illustrations. 7 figures. 8 tables. 4 references.
Full Record Printer Friendly Version
Erectile Dysfunction and Other Urological Issues in the Transplant Patient. In: Medical Management of Kidney Transplantation. Philadelphia, PA: Lippincott Williams and Wilkins. 2005. pp. 449-472.
Genitourinary complications commonly affect the kidney transplant population. This chapter on erectile dysfunction (ED) and other urological issues in kidney transplant recipients is from a textbook on the medical management of kidney transplant patients. The authors discuss the epidemiology of ED, erectile anatomy and physiology, the etiology of ED in the transplant patient (vasculogenic, neurogenic, endocrinologic causes, as well as chronic disease), and the evaluation of ED in the transplant patient, including the history and physical, laboratory studies, the process of care model, endocrine evaluation, treatment of hypogonadism, psychiatric factors of sexual dysfunction, phosphodiesterase type 5 inhibitors, vacuum constriction devices, transurethral alprostadil, intracavernosal injection, and penile prostheses. The final sections consider preoperative urological issues, including indications for native nephrectomy and history of urological malignancy; and postoperative urological issues, including hematuria, hydronephrosis and obstruction, urinary tract infections, prostate cancer screening, urolithiasis (urinary tract stones), and bladder dysfunction. The authors conclude that a thorough understanding of the urological issues involved and the diagnostic and treatment options available enables an effective multidisciplinary approach to the transplant patient. 14 figures. 7 tables. 138 references.
Full Record Printer Friendly Version
Erectile Dysfunction: Causes, Risks and Talking to Your Doctor. Linthicum, MD: American Urologic Association Foundation. 2005. 10 p.
This brochure, the first in a three-part series, focuses on erectile dysfunction (ED), defined as the persistent inability to get or maintain an erection firm enough for satisfactory sexual intercourse. The brochure explains the condition of ED, how erections occur, the causes of ED (physical, psychological, and as a side effect of medications), risk factors for ED, working with a health care provider to manage ED, what to expect at the doctor’s office for diagnosis and testing, and information for the sexual partners of men with ED. One section provides accurate information regarding some myths about ED. A glossary of terms concludes the brochure. The brochure includes blank space for reader notes or questions to ask one’s health care provider. The brochure emphasizes that many cases of ED can be treated successfully, but accurate diagnosis is the first step to management so readers are encouraged to consult their health care provider with any concerns about erectile function. 2 figures.
Full Record Printer Friendly Version
What I Need to Know About Erection Problems. Bethesda, MD: National Kidney and Urologic Diseases Information Clearinghouse, 2005. 17 p.
This booklet helps readers understand the problem of erectile dysfunction (ED, formerly called impotence) and how it can be managed. Written in nontechnical language, the booklet describes the causes of a normal erection and what can cause ED, what to expect in the doctor’s office for a visit regarding ED, and how the problem is treated. The booklet emphasizes most of the causes of ED are health problems requiring treatment to help prevent even more serious complications than ED. High blood pressure and high cholesterol can injure the arteries that supply blood to the penis. Diabetes injures blood vessels and the nerves that control erections. Alcohol and drug abuse can cause ED by damaging blood vessels and deadening the nerves that control erections. Some prescription drugs such as some antidepressants and some hypertension medicines can cause ED. Unhealthy habits, including smoking, overeating, and avoiding exercise can also contribute to ED. Treatments for prostate cancer, including radiation and prostate removal, can damage the nerves that control erections. Treatment options for ED can include lifestyle changes, counseling, oral medication, injection drugs, a vacuum erection device, and penile implants. The booklet concludes with a list of organizations, through which readers can find a health care provider or counselor, and additional information about ED. A final section briefly describes the goals and activities of the National Kidney and Urologic Diseases Information Clearinghouse. The booklet is illustrated with black-and-white line drawings. 7 figures.
Full Record Printer Friendly Version
Are They Better than Viagra?. Harvard Health Letter. 29(3): 3. January 2004.
This brief article, from a health newsletter, describes two new drugs designed to treat erectile dysfunction (ED, formerly called impotence). The Food and Drug Administration (FDA) approved vardenafil (Levitra) in August 2003 and tadalafil (Cialis) in November 2003. The author describes the differences between these drugs and sildenafil (Viagra) in dosage, initiation of effect, duration of effect, and side effects.
Full Record Printer Friendly Version
Alternative Medicine for ED: Is there a Rule?. Part I. Contemporary Urology. 15(8): 44-46, 48, 50-51, 55-57. August 2003.
Interest in complementary or alternative medicine (CAM) has grown enormously around the world over the past decade. The most rapidly increasing area of CAM is the use of dietary supplements, including herbs, vitamins, minerals, and other compounds. This article is the first part in a 2-part report on the use of supplements and acupuncture for treating erectile dysfunction (ED). This section summarizes current research findings, the limited government oversight into these products, the placebo effects, quality control, amino acid supplements, anabolic steroid supplements, and acupuncture as a treatment for ED. The second article (Contemporary Urology, September 2003) covers herbal and dietary supplements for ED and the impact of lifestyle modifications. 2 tables. 85 references.
Full Record Printer Friendly Version
An Evidence-Based Approach to Dietary Supplements for ED. Part 2. Contemporary Urology. 15(9): 49-50, 52, 55-56, 59. September 2003.
Interest in complementary or alternative medicine (CAM) has grown enormously around the world over the past decade. The most rapidly increasing area of CAM is the use of dietary supplements, including herbs, vitamins, minerals, and other compounds. This article is the second part of a 2-part report on the use of supplements and acupuncture for treating erectile dysfunction (ED). This section covers herbal and dietary supplements for ED, including gingko biloba, yohimbine, zinc, Korean red ginseng, avena sativa, Tribulus terrestric, and damiana. An additional section considers the impact of lifestyle modifications. The first article (Contemporary Urology, August 2003) summarizes current research findings, the limited government oversight into these products, the placebo effects, quality control, amino acid supplements, anabolic steroid supplements, and acupuncture as a treatment for ED. 1 table. 59 references.
Full Record Printer Friendly Version
Are Erectile and Ejaculatory Dysfunction Associated with Postmicturition Dribble?. Urologic Nursing. 23(1): 42-45, 48-52. February 2003.
In this article, the author examined research findings from two earlier literature reviews to determine if there may be an association between erectile dysfunction (ED, formerly called impotence) and postmicturition (after urination) dribble. From the review, the author notes that bulbocavernosus and ischiocavernosus muscle dysfunction may be responsible for both erectile and ejaculatory dysfunction, as well as a cause of postmicturition dribble and loss of the postvoid milking reflex. Pelvic floor muscle exercises may help to improve these conditions. However, research to investigate the conclusions proposed is necessary for an association or relationship to be stated conclusively. 3 figures. 1 table. 44 references.
Full Record Printer Friendly Version
Erectile Dysfunction. Mayo Clinic Health Letter. 21(10): 4-5. October 2003.
This newsletter article reviews the current treatment options available for erectile dysfunction (ED, formerly called impotence). The author cautions that while most men with ED see it only as interfering with their sexual performance, sometimes ED can be a first indication of other diseases. The article reviews the normal physiological changes that occur with age; the causes of erectile dysfunction, including chronic diseases and disorders surgery or trauma, medications, substance abuse, and psychological disorders; reasons to consult with a physician or other health care providers; and treatment strategies, including oral medications, injected drugs, self-administered intraurethral therapy, vacuum devices, and surgery. 1 figure.
Full Record Printer Friendly Version
How to Choose Among the PDE5 Inhibitors for Erectile Dysfunction. Patient Care. 37(11): 52-57, 61. November 2003.
With two safe and effective drugs for erectile dysfunction (ED) on the market and a third close to Food and Drug Administration (FDA) approval, physicians need to know how the differences among them can help to meet patients' needs. This article explores how to choose among the PDE5 inhibitors for ED. Success rates of these drugs are comparable. The authors contend that selection among the three drugs may be based on differences in attributes such as duration of action, PDE selectivity, adverse-effect profile, dosing issues, impact of food coadministration on drug efficacy, and patient preference. Sildenafil has the most extensive track record, but also has some side effects including impedance of action by food, particularly fatty foods. Vardenafil appears to achieve maximum plasma concentration more rapidly than either sildenafil or tadalafil, an attribute which may translate into greater rapidity of onset of action. Tadalafil has the longest half-life of the three, about 18 hours, and there is no reduction in absorption when taken with food. One sidebar describes the physiology of erection and the mechanism of action of sildenafil; another discusses the use of a treadmill test to assess the cardiovascular risk in patients who have ED. 1 figure. 2 tables. 10 references.
Full Record Printer Friendly Version
Managing Erectile Dysfunction in the Coronary Patient. Contemporary Urology. 15(12): 50-52, 54-55. December 2003.
This article offers physicians an update on management strategies for erectile dysfunction (ED) in the patient with coronary artery disease. The author notes that many of the major risk factors for coronary artery disease (CAD), i.e., smoking, hypertension, lipid abnormalities, diabetes, obesity, and lack of physical exercise, are also risk factors for vasculogenic ED. The author reviews the classification of patients into risk factor categories, then considers the use of drug therapy (such as sildenafil citrate or Viagra) in these patients. The author describes the use of the Princeton Consensus Guidelines that were developed as a practical set of recommendations for addressing sexual dysfunction in the cardiac patient. A final section addresses strategies for managing acute ischemia. 1 figure. 29 references.
Full Record Printer Friendly Version
Pelvic Floor Muscle Exercises and Manometric Biofeedback for Erectile Dysfunction and Postmicturition Dribble: Three Case Studies. Journal of WOCN. (Wound, Ostomy and Continence Nursing). 30(1): 44-52. January 2003.
This article presents three successful case studies of men receiving treatment for erectile dysfunction (ED) and postmicturition dribble, to alert nurses to the possible benefits of pelvic floor muscle exercises for men. Postmicturition dribble is the complaint of a dribbling loss of urine that occurs after voiding. The authors report on the training program for the three cases. Each of the three subjects reported normal erectile function following pelvic floor muscle exercise (PFME) and manometric biofeedback. PFME, which included a 'squeeze out' pelvic floor muscle contraction after voiding urine, alleviated the small amount of postmicturition dribble experienced by two subjects. Manometric biofeedback was chosen as a reliable method of monitoring anal pressure measurements. 5 figures. 3 tables. 22 references.
Full Record Printer Friendly Version
Pelvic Floor Muscle Exercises and Manometric Biofeedback for Erectile Dysfunction and Postmicturition Dribble: Three Case Studies. Journal of WOCN. Wound, Ostomy, and Continence Nurses Society. 30(1): 44-52. January 2003.
This article presents three successful case studies of men receiving treatment for erectile dysfunction (ED, formerly called impotence) and postmicturition dribble (leakage of urine immediately after urination). The authors focus on the benefits of pelvic floor muscle exercises (PFME) for these men. Each of the three subjects reported normal erectile function following PFME and manometric biofeedback. Manometric biofeedback was chosen as a reliable method of monitoring anal pressure measurements. PFME, which included a 'squeeze out' pelvic floor muscle contraction after voiding urine, alleviated the small amount of postmicturition dribble experienced by two subjects. These case studies are reported to alert professionals to the possibility of the benefits of PFME for some men. A commentary is appended to the article. 2 figures. 3 tables. 20 references.
Full Record Printer Friendly Version
Salvage of Sildenafil Failures Referred From Primary Care Physicians. Journal of Urology. 170(6): 2356-2358. December 2003.
Sildenafil citrate (Viagra) is an effective first line agent for most causes of erectile dysfunction (ED). Primary care providers (PCPs) write the majority of these prescriptions and most failures of sildenafil therapy are subsequently referred to urologists for alternative therapies. Often it is concluded that the drug is ineffective when in actuality the failure is due to inadequate patient education. This article reports on a study of patients referred from PCPs who were nonresponders to sildenafil therapy and who the authors attempted to convert to responders through re-education. Of the 253 patients re-educated, 17 were excluded due to contraindications. Of the remaining nonresponders, 41.5 percent achieved salvage with re-education. Incorrect administration accounted for 81 percent of the failures. Average time with the physician was 12 minutes and 94 percent of the patients continued to respond at 26 months. The authors conclude that new package materials may improve sildenafil outcomes and compliance. 1 appendix. 2 figures. 3 tables. 10 references.
Full Record Printer Friendly Version
Sexual Function in Men Older Than 50 Years of Age: Results from the Health Professionals Follow-up Study. Annals of Internal Medicine. 139(3): 161-168. August 2003.
Although many studies have provided data on erectile dysfunction (ED, formerly called impotence) in specific settings, few studies have been large enough to precisely examine age-specific prevalence and correlates. This article reports on a study undertaken to describe the association between age and several aspects of sexual functioning in men older than 50 years of age. The cross-sectional analysis of data from a prospective cohort study included 31,742 men, aged 53 to 90 years. Questionnaires mailed in 2000 asked about sexual function, physical activity, body weight, smoking, marital status, medical conditions, and medications. When men with prostate cancer were excluded, the results showed age-standardized prevalence of ED in the previous 3 months was 33 percent. Many aspects of sexual function (included overall function, desire, orgasm, and overall ability) decreased sharply by decade after 50 years of age. Physical activity was associated with lower risk for ED and obesity was associated with higher risk. Smoking, alcohol consumption, and television viewing time were also associated with increased prevalence of ED. Men who had no chronic medical conditions and who engaged in healthy behaviors had the lowest prevalence of ED. The authors concludes that several modifiable health behaviors are associated with maintenance of good erectile function. 1 figure. 4 tables. 33 references.
Full Record Printer Friendly Version
Smoking and Erectile Dysfunction: How Strong a Link?. Contemporary Urology. 15(3): 34, 36-38, 40. March 2003.
Although the exact effect of smoking on penile function remains unclear, numerous studies suggest a correlation between smoking and erectile dysfunction (ED, formerly called impotence). This article examines what is currently known, and what remains to be discovered, about this link. ED is defined as the inability to achieve and maintain a penile erection sufficient for sexual intercourse. Topics include the physiology of erection, clinical evidence linking smoking and ED, the effect of smoking cessation, epidemiological evidence, and the interplay of smoking and oral pharmacotherapy (notably with sildenafil, Viagra). The authors conclude that more basic science and clinical investigation is necessary to ascertain the exact effects that smoking has on erectile function. 1 table. 28 references.
Full Record Printer Friendly Version
Use of Medications for Erectile Dysfunction in the United States, 1996 Through 2001. Journal of Urology. 169(3): 1040-1042. March 2003.
This article reports on a review of the use during 1996 through 2001 of the primary medications approved in the United States for treatment of erectile dysfunction (ED), namely alprostadil injection and urethral suppository, and oral sildenafil (Viagra). Increases in the number of dispensed prescriptions for alprostadil injection and urethral suppository marketed in 1995 and 1996, respectively, were reversed in 1998 by the marketing of sildenafil. Sildenafil was prescribed proportionately more frequently for younger men than alprostadil injection or suppository. Alprostadil was prescribed proportionately more frequently by urologists than sildenafil, which was most commonly prescribed by family and general practitioners, and internists. The data indicate the wide adoption and use of sildenafil for erectile dysfunction. 3 tables. 18 references.
Full Record Printer Friendly Version
Displaying all search results.
Start a new search.
|
